Cinacalcet: will it play a role in reducing cardiovascular events?

Area of Science:

• Nephrology
• Endocrinology
• Cardiology

Background:

• Secondary hyperparathyroidism (SHPT) is a frequent complication of chronic kidney disease (CKD), linked to significant morbidity and mortality.
• SHPT involves elevated parathyroid hormone (PTH) levels, increased bone turnover, and adverse cardiovascular effects like calcification and cardiomyopathy.
• Current management of SHPT in CKD patients presents ongoing challenges.

Purpose of the Study:

• To review the role of cinacalcet, a calcimimetic agent, in managing SHPT.
• To explore cinacalcet's potential in preventing and mitigating cardiovascular calcification and uremic cardiomyopathy in CKD.
• To examine the calcium-sensing receptor (CaSR) as a therapeutic target in CKD-related cardiovascular disease.

Main Methods:

• Review of existing literature on secondary hyperparathyroidism, chronic kidney disease, and calcimimetics.
• Analysis of cinacalcet's mechanism of action as a calcimimetic and its effect on the CaSR.
• Examination of studies investigating cardiovascular outcomes in CKD patients treated with cinacalcet.

Main Results:

• Cinacalcet effectively reduces parathyroid hormone levels by activating the CaSR, thereby inhibiting PTH secretion.
• Evidence suggests cinacalcet may play a role in preventing or slowing cardiovascular calcification in CKD patients.
• The CaSR's presence in cardiovascular tissues indicates its potential involvement in CKD-related cardiovascular pathophysiology.

Conclusions:

• Cinacalcet is an effective oral therapy for SHPT in CKD, offering benefits beyond PTH reduction.
• Targeting the CaSR with cinacalcet presents a promising therapeutic strategy for cardiovascular complications in CKD.
• Further research is warranted to fully elucidate cinacalcet's cardiovascular protective effects in the CKD population.